
Stereotaxis (NYSE:STXS) announced today that it completed the world’s first commercial procedures using its Magic Sweep catheter.
The MAGiC Sweep catheter is a high-density electrophysiology EP mapping catheter designed for use with Stereotaxis’ Robotic Magnetic Navigation systems. Dr. Raffaele Corbisiero and Dr. Pedram Kazemian performed the procedures at Deborah Heart and Lung Center in Browns Mills, New Jersey.
Stereotaxis won FDA clearance for the Magic Sweep catheter in July.
“We’re excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients,” said Dr. Corbisiero, chief of electrophysiology at Deborah Heart and Lung Center. “The ability to create a more accurate, detailed map of complex anatomy is important in diagnosing and treating arrhythmias. We have been impressed with the catheter during our experience mapping several different arrhythmias in the atria and ventricles.”
High-density mapping enhances cardiac ablation procedures through more efficient, detailed and precise identification of arrhythmia origin. Stereotaxis says the clearance marks a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.
Equipped with 20 electrodes, Magic Sweep facilitates rapid and detailed electroanatomical mapping of the heart chambers. It integrates seamlessly with Stereotaxis’ robotic systems to enable precise navigation to otherwise difficult-to-reach areas of the heart.
Stereotaxis said it included an atraumatic design, including an atraumatic shaft, to prioritize patient safety. The catheter supports more anatomically accurate maps by avoiding the distension caused by rigid catheters and enables improved robotic procedural workflows, particularly as the company advances algorithms that support automated mapping.
“This is a significant leap forward for the community of robotic electrophysiologists and we look forward to the positive impact its expanded use will have on our patients and the EP field,” said Kazemian.
